Evaluating the Effectiveness of the Charlson Comorbidity Index in Predicting Immune Checkpoint Inhibitor-Related Adverse Events-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Evaluating the Effectiveness of the Charlson Comorbidity Index in Predicting Immune Checkpoint Inhibitor-Related Adverse Events

Published:2024-01-30 Issue:5 Volume:16 Page:295-303
ISSN:1750-743X
Container-title:Immunotherapy
language:en
Short-container-title:Immunotherapy

Author:

Onur İlknur Deliktaş¹^ORCID,Mutlu Emel²,Sertesen Elif¹,Önder Tuğba¹,Duran Ayşe Ocak¹,İnanç Mevlüde²

Affiliation:

1. Health Sciences University, Dr Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Department of Medical Oncology, Ankara, 06200, Turkey

2. Department of Medical Oncology, Erciyes University Faculty of Medicine, Kayseri, 38039, Turkey

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.2217/imt-2023-0270

Reference16 articles.

1. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

2. Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials

3. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1

4. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation

5. Cancer Statistics, 2021

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COMORBIDITY IN ONCOLOGY: MODERN CHALLENGES AND THE SEARCH FOR WAYS TO SOLVE THE PROBLEM;Clinical and Preventive Medicine;2024-05-08

2. Nivolumab;Reactions Weekly;2024-05-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP